Palivizumab 12714-0232
Product NDC
12714-0232- Manufacturer
- Boehringer Ingelheim Pharma Gmbh And Co. Kg
- Dosage Form
- Solution
- Product Type
- Drug For Further Processing
- Marketing Start
- June 24, 2016
- Listing Expires
- December 31, 2026
Active Ingredients
| Ingredient | Strength |
|---|---|
| Palivizumab | 100 mg/100mg |
Packaging Options(1)
100 mg in 1 VIAL, SINGLE-DOSE (12714-232-10)